Oncolytic virus · Kills target cells · developed by Replimune
RP3 is a genetically modified herpes simplex type 1 virus, classed as an oncolytic virus, studied in refractory metastatic colorectal cancer that is mismatch repair proficient and microsatellite stable.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05733611 | Phase 2 | Refractory Metastatic Colorectal Cancer | Terminated | REPL |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
MSSpMMRRefractory Metastatic Colorectal Cancer
Updated Nov 1, 2026. Something wrong or missing? Report it on the REPL page.
See REPL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
REPL catalysts and pipeline →